Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +42

Citigroup Boosts Abbott Laboratories (NYSE:ABT) Price Target to $112.00

AI-generated analysis

📈 Citigroup raises Abbott Laboratories price target to $112.00 from $108.00 with a 'buy' rating.

📉 Raymond James Financial lowers target to $115.00 while Bank of America cuts objective to $102.00.

💰 Q3 EPS beat consensus at $1.31 versus an expected $1.28.

📊 Revenue grew 13.0% year-over-year to reach $12.51 billion for the quarter.

🎯 Company guidance set for Q3 2026 EPS between $1.38 and $1.46.

👔 Director Daniel J. Starks buys 10,000 shares worth over $926,000.

💼 CFO Philip P. Boudreau acquires 2,200 shares for approximately $201,300.

🏦 Institutional ownership stands at 75.18% with new stakes from multiple funds.

📉 Consensus analyst target price averages $118.61 based on MarketBeat data.

🔬 Company operates globally in diagnostics, medical devices, nutritionals, and pharmaceuticals.

Bullish Signals
  • Citigroup increased its price target to $112.00, signaling confidence in the stock's upside potential of 11.21% from the previous close.
  • Abbott Laboratories beat quarterly EPS estimates by $0.03, reporting $1.31 per share against a consensus of $1.28.
  • Revenue grew robustly by 13.0% year-over-year to reach $12.51 billion, demonstrating strong top-line growth.
  • Director Daniel J. Starks purchased 10,000 shares at an average price of $92.65, increasing his total holdings significantly.
  • CFO Philip P. Boudreau bought 2,200 shares for $201,300, indicating insider confidence in the company's future prospects.
  • The company maintains healthy financial metrics with a net margin of 11.65% and a return on equity of 17.65%.
Risk Factors
  • Bank of America reduced its price objective to $102.00, suggesting some analysts see limited upside or potential headwinds.
  • Raymond James Financial lowered their price target from $130.00 to $115.00, indicating a more cautious outlook compared to previous valuations.
  • Mizuho Securities cut its target to $115.00 and assigned a 'neutral' rating, reflecting uncertainty about future performance.
Full Analysis
Citigroup has raised its price target for Abbott Laboratories (NYSE:ABT) to $112.00 from $108.00, maintaining a 'buy' rating and indicating potential upside of 11.21% from the previous close. This move follows a mixed analyst landscape where Raymond James Financial lowered their target to $115.00 with an 'outperform' rating, while Bank of America reduced theirs to $102.00. Sanford C. Bernstein also cut their target to $110.00 but kept an 'outperform' stance, whereas Mizuho reduced their target to $115.00 and assigned a 'neutral' rating. Abbott Laboratories recently reported quarterly earnings on July 16th, delivering $1.31 in EPS which beat the consensus estimate of $1.28 by $0.03. Revenue reached $12.51 billion, slightly missing the $12.52 billion consensus but growing 13.0% year-over-year. The company achieved a net margin of 11.65% and a return on equity of 17.65%. For the current fiscal year, management has guided EPS between $5.45 and $5.60, while analysts average an expectation of $5.48. Corporate insider activity shows Director Daniel J. Starks purchasing 10,000 shares at an average price of $92.65, increasing his stake by 0.15% to a total value exceeding $625 million. CFO Philip P. Boudreau also bought 2,200 shares for approximately $201,300. Institutional ownership remains high at 75.18%, with several funds like MidAtlantic Capital Management and Cornerstone Financial Management acquiring new positions in the fourth quarter.